Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499731 | 0.80 | USP2 (0.48) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| SCHEMBL7573117 | 0.76 | ALDH1A1 (0.36) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| SCHEMBL2105323 | 0.75 | USP2 (0.43) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| SCHEMBL576641 | 0.73 | — | — | |
| SCHEMBL29261040 | 0.71 | — | — | |
| SCHEMBL9423551 | 0.71 | — | — | |
| SCHEMBL9228917 | 0.71 | — | — | |
| SCHEMBL6165681 | 0.71 | USP2 (0.40) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| SCHEMBL576900 | 0.71 | USP2 (0.40) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| SCHEMBL7574075 | 0.71 | KDM4E (0.32) | ALDH1A1KDM4EUSP2LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411388-A1 | SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-29 | — | — | US | disclosed |
| EP-4031531-A1 | SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Bial-R&D Investments, S.A. (PT) | 2022-07-27 | — | — | EP | disclosed |
| WO-2021055612-A1 | SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL-BioTech Investments, Inc. (US) | 2021-03-25 | — | — | WO | disclosed |
| US-9624234-B2 | Heterocyclic compounds and methods for their use | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| US-20150218180-A1 | Heterocyclic compounds and methods for their use | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-08-06 | — | — | US | disclosed |
| US-20150218180-A1 | Heterocyclic compounds and methods for their use | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-08-06 | — | — | US | disclosed |
| WO-2013110135-A1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2013-08-01 | — | — | WO | disclosed |
| EP-0810199-B1 | Method for producing propargylamine compounds | SUMITOMO CHEMICAL CO (JP) | 2002-09-25 | — | — | EP | disclosed |
| US-5756769-A | Method for producing propargylamine compounds | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 1998-05-26 | — | — | US | disclosed |
| EP-0810199-A1 | Method for producing propargylamine compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218180-A1 | Heterocyclic compounds and methods for their use | AGTR2, AGTR1, OPRL1 | ALDH1A1 2203/4885KDM4E 3369/4885USP2 2808/4885 |
| US-20220411388-A1 | SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, CLN6 | ALDH1A1 1398/4885KDM4E 701/4885USP2 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.